People · Operator
Named in public records as an officer, director or promoter · active 2017–2017 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Madrigal Pharmaceuticals, Inc. | — | Pharmaceuticals | Series B | $35.0M | $1.2B | 2017 |
David R. Milligan at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside David R. Milligan on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Richard S. Levy | 1 | 4 |
| Fred B. Craves | 1 | 3 |
| Kenneth M. Bate | 1 | 3 |
| Paul A. Friedman | 1 | 2 |
| Marc R. Schneebaum | 1 | 2 |
| Rebecca A. Taub | 1 | 2 |
| Keith R. Gollust | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.